Drug Development
51 articles RSS
Keytruda Becomes First Immunotherapy to Extend Survival in Platinum-Resistant Ovarian Cancer
FDA approves pembrolizumab for a subset of ovarian cancer patients after Phase 3 KEYNOTE-B96 trial shows the first overall survival benefit ever demonstrated by an immunotherapy in this setting.
4 min read3 sources
Merck's Once-Daily Cholesterol Pill Matches Injectable Efficacy in Phase 3 Trial, Opening Path to First Oral PCSK9 Inhibitor
Enlicitide decanoate cut LDL cholesterol by 57% in 2,900+ patients in the CORALreef Lipids Phase 3 trial — matching injectable PCSK9 inhibitors in pill form, with no meaningful safety signals over 52 weeks.
4 min read3 sources
Scientists Identify the Enzyme That Shatters Chromosomes in One in Four Cancers, Revealing a New Target for Drug Resistance
UC San Diego researchers identify N4BP2 as the molecular trigger behind chromothripsis, the catastrophic chromosome-shattering event that drives treatment resistance in roughly a quarter of human cancers.
4 min read4 sources